Exelixis, Inc.
Could not find a ticker for this position, may be a filing error
A biopharmaceutical company that makes cancer medicines, most notably cabozantinib, sold in the U.S. as CABOMETYX for kidney and liver cancers and as COMETRIQ for a rare thyroid cancer. Founded in 1994 by scientists from Yale and UC Berkeley who began by studying fruit flies and zebrafish to find drug targets, the company is now a fully integrated oncology drugmaker. Its name comes from the Greek word for "evolution," a nod to how the firm itself evolved from a genomics startup into a commercial drug company.
4.25% Convertible Senior Subordinated Notes Due 2019
Granted 11.22M · Bought 30.0K · Sold 2.73M
Granted 18.2K · Bought 762.9K · Sold 120.4K
Granted 618.1K · Bought 500.0K · Sold 574.5K
Granted 2.57M · Sold 790.2K
Granted 1.91M · Sold 1.20M
Granted 584.1K · Bought 25.0K · Sold 1.36M
Granted 2.55M · Bought 25.0K · Sold 1.78M
Granted 2.52M · Sold 1.16M
Granted 1.13M · Sold 499.3K
Granted 573.7K · Sold 72.8K
Granted 372.0K · Bought 456.2K · Sold 441.3K
Granted 2.44M · Sold 1.75M
Granted 332.6K
Granted 527.4K · Sold 243.0K
Granted 424.2K · Sold 357.8K
Granted 53.3K · Sold 25.3K
Granted 550.0K · Sold 422.8K
Granted 190.5K · Sold 81.3K
Granted 31.3K · Bought 34.0K
Granted 446.0K · Bought 42.0K · Sold 404.0K
Granted 358.7K · Sold 333.3K
Granted 370.9K · Sold 335.2K
Granted 51.8K
Granted 55.2K · Sold 4.5K
Granted 79.4K · Sold 48.9K
Granted 241.3K · Sold 207.6K
Granted 95.6K · Sold 65.6K
Granted 70.4K · Sold 44.5K
Granted 136.1K · Sold 119.1K
Granted 6.4K
Granted 15.6K · Sold 13.1K
Granted 60.2K · Sold 44.1K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Morrissey MichaelPresident and CEO, Director · 321 transactions | — | 8.36M | 11.22M | 30.0K | 2.73M |
| Caligan Partners LP +1 co-filerDirector, See Remarks, Director · 7 transactions | — | 1.57M | 18.2K | 762.9K | 120.4K |
| Papadopoulos SteliosDirector · 77 transactions | — | 1.20M | 618.1K | 500.0K | 574.5K |
| Senner Christopher J.EVP and CFO · 98 transactions | — | 955.0K | 2.57M | — | 790.2K |
| Haley Patrick J.EVP, Commercial · 167 transactions | — | 783.2K | 1.91M | — | 1.20M |
| Scangos George ADirector · 1726 transactions | — | 738.3Kas of May 2020 | 584.1K | 25.0K | 1.36M |
| Schwab GiselaPres, Prod Dev & Med Aff & CMO · 141 transactions | — | 704.0Kas of Jul 2021 | 2.55M | 25.0K | 1.78M |
| Hessekiel JeffreyEVP & General Counsel · 133 transactions | — | 694.4Kas of May 2025 | 2.52M | — | 1.16M |
| Aftab DanaEVP, Research and Development · 48 transactions | — | 600.6K | 1.13M | — | 499.3K |
| Peterson Amy C.EVP Prod Dev & Med Aff & CMO · 8 transactions | — | 538.2Kas of May 2025 | 573.7K | — | 72.8K |
| Willsey LanceDirector · 78 transactions | — | 464.4Kas of May 2022 | 372.0K | 456.2K | 441.3K |
| Lamb PeterEVP, Scientific Strategy & CSO · 168 transactions | — | 428.1Kas of Dec 2022 | 2.44M | — | 1.75M |
| Goodman Vicki LEVP, Prod Dev & Med Aff &CMO · 4 transactions | — | 307.7Kas of Apr 2023 | 332.6K | — | — |
| Wyszomierski Jack LDirector · 40 transactions | — | 284.4K | 527.4K | — | 243.0K |
| Cohen CharlesDirector · 45 transactions | — | 221.4Kas of Jul 2021 | 424.2K | — | 357.8K |
| Hefti BrendaSVP and General Counsel · 6 transactions | — | 208.3K | 53.3K | — | 25.3K |
| Poste GeorgeDirector · 44 transactions | — | 127.2K | 550.0K | — | 422.8K |
| Freire Maria CDirector · 17 transactions | — | 109.2K | 190.5K | — | 81.3K |
| Karbe FrankEVP and CFO · 29 transactions | — | 106.7Kas of Feb 2014 | 31.3K | 34.0K | — |
| Marchesi Vincent TDirector · 53 transactions | — | 94.0Kas of May 2022 | 446.0K | 42.0K | 404.0K |
| Feldbaum Carl BDirector · 36 transactions | — | 58.7Kas of Feb 2023 | 358.7K | — | 333.3K |
| Garber Alan MDirector · 29 transactions | — | 54.9Kas of Mar 2024 | 370.9K | — | 335.2K |
| Wright JacquelineDirector · 3 transactions | — | 51.8Kas of Jun 2023 | 51.8K | — | — |
| Heyman Tomas J.Director · 5 transactions | — | 50.6K | 55.2K | — | 4.5K |
| Oliver BobDirector · 10 transactions | — | 29.5K | 79.4K | — | 48.9K |
| Smith JulieDirector · 19 transactions | — | 29.0K | 241.3K | — | 207.6K |
| Simonton Pamela AEVP, Exelixis · 47 transactions | — | 28.1Kas of Feb 2014 | 95.6K | — | 65.6K |
| Beckerle Mary CDirector · 12 transactions | — | 25.9K | 70.4K | — | 44.5K |
| Rivera Lupe MEVP, Operations · 29 transactions | — | 22.1Kas of Aug 2011 | 136.1K | — | 119.1K |
| Burke DeborahSVP & Chief Financial Officer · 6 transactions | — | 21.2Kas of Nov 2014 | 6.4K | — | — |
| Heller Frances KEVP, Business Development · 8 transactions | — | 17.3Kas of May 2011 | 15.6K | — | 13.1K |
| Eckhardt Sue GailDirector · 11 transactions | — | 16.1K | 60.2K | — | 44.1K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: -13.35M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.